Synergetic Effects of PARP Inhibitor AZD2281 and Cisplatin in Oral Squamous Cell Carcinoma in Vitro and in Vivo
Authors:
- Masaaki YasukawaMYMasaaki Yasukawa
- Hisako FujiharaHFHisako Fujihara
- Hiroaki FujimoriHFHiroaki Fujimori
- Koji KawaguchiKKKoji Kawaguchi
- Hiroyuki YamadaHYHiroyuki Yamada
- Ryoko NakayamaRNRyoko Nakayama
- Nanami YamamotoNYNanami Yamamoto
- Yuta KishiYKYuta Kishi
- Yoshiki HamadaYHYoshiki Hamada
- Mitsuko MasutaniMMMitsuko Masutani
Open Access
- 24 February 2016
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 17 (3) , 272
Abstract
Cisplatin is a commonly used chemotherapeutic drug for treatment of oral carcinoma, and combinatorial effects are expected to exert greater therapeutic efficacy compared with monotherapy. Poly(ADP-ribosyl)ation is reported to be involved in a variety of cellular processes, such as DNA repair, cell death, telomere regulation, and genomic stability. Based on these properties, poly(ADP-ribose) polymerase (PARP) inhibitors are used for treatment of cancers, such as BRCA1/2 mutated breast and ovarian cancers, or certain solid cancers in combination with anti-cancer drugs. However, the effects on oral cancer have not been fully evaluated. In this study, we examined the effects of PARP inhibitor on the survival of human oral cancer cells in vitro and xenografted tumors derived from human oral cancer cells in vivo. In vitro effects were assessed by microculture tetrazolium and survival assays. The PARP inhibitor AZD2281 (olaparib) showed synergetic effects with cisplatin in a dose-dependent manner. Combinatorial treatment with cisplatin and AZD2281 significantly inhibited xenografted tumor growth compared with single treatment of cisplatin or AZD2281. Histopathological analysis revealed that cisplatin and AZD2281 increased TUNEL-positive cells and decreased Ki67- and CD31-positive cells. These results suggest that PARP inhibitors have the potential to improve therapeutic strategies for oral cancer.Keywords
Funding Information
- Japan Society for the Promotion of Science (15K11286, 25463157, 24593041, 21592491)
This publication has 36 references indexed in Scilit:
- Role of poly(ADP-ribose) polymerase-1 in the removal of UV-induced DNA lesions by nucleotide excision repairProceedings of the National Academy of Sciences, 2013
- Inhibition of Poly(ADP-Ribose) Polymerase-1 Enhances Temozolomide and Topotecan Activity against Childhood NeuroblastomaClinical Cancer Research, 2009
- Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology ConsortiumCancer Epidemiology, Biomarkers & Prevention, 2009
- High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugsProceedings of the National Academy of Sciences, 2008
- Platinum-Based Chemotherapy plus Cetuximab in Head and Neck CancerNew England Journal of Medicine, 2008
- Poly(ADP-Ribose) Polymerase 1 Accelerates Single-Strand Break Repair in Concert with Poly(ADP-Ribose) GlycohydrolaseMolecular and Cellular Biology, 2007
- Structural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell, 2005
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Cancer genes and the pathways they controlNature Medicine, 2004
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003